Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.

ABSTRACT:

Purpose

Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that is associated with poor clinical outcome. There is a vital need for effective targeted therapeutics for TNBC patients, yet treatment strategies are challenged by the significant intertumoral heterogeneity within the TNBC subtype and its surrounding microenvironment. Receptor tyrosine kinases (RTK) are highly expressed in several TNBC subtypes and are promising therapeutic targets. In this study, we targeted the MET receptor, which is highly expressed across several TNBC subtypes.

Experimental design

Using the small-molecule inhibitor cabozantinib (XL184), we examined the efficacy of MET inhibition in preclinical models that recapitulate human TNBC and its microenvironment. To analyze the

SUBMITTER: Sameni M 

PROVIDER: S-EPMC5500174 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature